Written and maintained by CASRAI Editorial Board
Last updated
The HAS-BLED score—derived and validated by Pisters et al. (Chest 2010;138(5):1093–1100) from the Euro Heart Survey on Atrial Fibrillation—is a 0-to-9-point clinical risk stratification tool used to estimate the 1-year risk of major bleeding (defined as intracranial hemorrhage, bleeding requiring hospitalization, a hemoglobin drop > 2 g/dL, and/or blood transfusion) in patients with atrial fibrillation (AF) considered for or receiving oral anticoagulation. In clinical practice and cardiology trials, HAS-BLED is paired alongside the CHA₂DS₂-VASc score to balance thromboembolic stroke prevention against hemorrhagic risk.
What Is the HAS-BLED Score and How Is It Calculated?
The HAS-BLED acronym comprises seven clinical domains—with two domains (A and D) capable of contributing up to 2 points each—yielding a maximum total score of 9 points:
| Letter | Clinical Risk Factor | Operational Definition (Pisters et al., Chest 2010) | Points |
|---|---|---|---|
| H | Hypertension | Uncontrolled systolic blood pressure > 160 mmHg | 1 |
| A | Abnormal Renal Function | Chronic dialysis, renal transplantation, or serum creatinine ≥ 200 μmol/L (≥ 2.26 mg/dL) | 1 |
| Abnormal Liver Function | Chronic hepatic disease (e.g., cirrhosis) or biochemical evidence of significant hepatic derangement: bilirubin > 2× ULN in association with AST/ALT/alkaline phosphatase > 3× ULN | 1 | |
| S | Stroke | Prior history of ischemic or hemorrhagic stroke | 1 |
| B | Bleeding History or Predisposition | Previous major bleeding episode or predisposition to bleeding (e.g., bleeding diathesis, anemia) | 1 |
| L | Labile INRs | Unstable or high International Normalized Ratios or poor Time in Therapeutic Range (TTR < 60%) on vitamin K antagonist (warfarin) therapy | 1 |
| E | Elderly | Age > 65 years (or extreme frailty) | 1 |
| D | Drugs Concomitantly | Concomitant use of medications predisposing to bleeding, specifically antiplatelet agents (aspirin, clopidogrel) or NSAIDs | 1 |
| Alcohol Concomitantly | Alcohol excess / abuse (defined as ≥ 8 drinks/units per week) | 1 |
Euro Heart Survey 1-Year Major Bleeding Rates by HAS-BLED Score
In the original Euro Heart Survey derivation cohort (3,978 patients with AF, including subsets detected via ambulatory ECG or Zio Patch monitoring), annual major bleeding incidence rose steeply once the HAS-BLED score reached ≥ 3 points (high risk):
- 0 points (Low risk): 1.13 major bleeds per 100 patient-years
- 1 point (Moderate risk): 1.02 major bleeds per 100 patient-years
- 2 points (Moderate risk): 1.88 major bleeds per 100 patient-years
- 3 points (High risk threshold): 3.74 major bleeds per 100 patient-years
- 4 points (High risk): 8.70 major bleeds per 100 patient-years
- 5 points (High risk): 12.50 major bleeds per 100 patient-years (scores > 5 were rare in the derivation cohort but carry >10% annual major bleed risk in external registries).
What Standards or Regulatory Guidelines Govern the HAS-BLED Score?
International cardiology clinical practice guidelines—including the European Society of Cardiology (ESC) Atrial Fibrillation Guidelines, the Asia Pacific Heart Rhythm Society (APHRS), and the ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation—establish two cardinal clinical rules for interpreting HAS-BLED:
- A High HAS-BLED Score (≥ 3) Is NOT a Reason to Withhold Anticoagulation: Because several risk factors in HAS-BLED (Hypertension, Stroke, Age > 65) overlap directly with the CHA₂DS₂-VASc stroke score, patients with a HAS-BLED score ≥ 3 almost always face an even higher absolute risk of devastating cardioembolic stroke if left un-anticoagulated. Instead, guidelines mandate using HAS-BLED to identify and correct modifiable bleeding risk factors—controlling systolic blood pressure below 160 mmHg, discontinuing unnecessary concomitant aspirin or NSAIDs, counseling on alcohol reduction, switching from labile warfarin (TTR < 60%) to a Direct Oral Anticoagulant (DOAC), and scheduling closer clinical follow-up.
- Comparative Validation Against ORBIT, ATRIA, and HEMORR₂HAGES Scores: In comparative validation studies evaluating discrimination via the C-statistic (AUROC) and net reclassification improvement, HAS-BLED outperformed older bleeding scores (such as HEMORR₂HAGES and ATRIA) in predicting intracranial hemorrhage and specifically captures Labile INR and reversible drug/alcohol interactions alongside the DOAC-era ORBIT bleeding score.
How Does the HAS-BLED Score Integrate with EHR and Health Informatics Workflows?
Within hospital electronic medical charting and anticoagulation management clinics, clinical decision support (CDS) rules automate HAS-BLED calculation alongside CHA₂DS₂-VASc:
- Automated EHR Data Extraction: The EHR CDS calculator queries the patient’s age (`Patient.birthDate`), most recent outpatient/inpatient systolic blood pressure flowsheet values, LOINC-coded serum creatinine, total bilirubin, AST, ALT, and alkaline phosphatase levels, automated Time in Therapeutic Range (Rosendaal TTR method across longitudinal PT/INR results), ICD-10-CM/SNOMED CT problem list codes for prior stroke, cirrhosis, dialysis, and major hemorrhage, and RxNorm medication lists for active aspirin, P2Y12 inhibitors, or NSAIDs.
- Clinical Trial Baseline Stratification: In Phase III randomized trials of novel oral anticoagulants (such as Factor XI/XIa inhibitors) and left atrial appendage occlusion (LAAO) devices, baseline HAS-BLED score (dichotomized at < 3 vs. ≥ 3) serves as a pre-specified subgroup stratification variable and inclusion criterion for patients with high bleeding risk.
Frequently Asked Questions
What is the HAS-BLED score and how is it used in clinical research and healthcare?
The HAS-BLED score is a 0-to-9-point clinical risk score that estimates 1-year major bleeding risk in patients with atrial fibrillation based on Hypertension (>160 mmHg), Abnormal renal or liver function (1 point each), Stroke history, Bleeding history/predisposition, Labile INRs (TTR <60%), Elderly age (>65), and concomitant Drugs (antiplatelets/NSAIDs) or alcohol (≥8 drinks/week, 1 point each). Clinicians use a score ≥ 3 to flag high-risk patients for modifiable risk-factor correction and closer follow-up, while clinical trials use it to stratify baseline bleeding risk.
What standards or regulatory requirements govern the HAS-BLED score?
Derived in the Euro Heart Survey (Pisters et al., Chest 2010) and endorsed in ESC and ACC/AHA/ACCP/HRS Atrial Fibrillation clinical practice guidelines, the HAS-BLED score is governed by the clinical principle that a high score (≥ 3) should prompt modification of reversible bleeding risk factors (uncontrolled hypertension, labile INRs, concomitant NSAIDs/aspirin, excess alcohol) rather than withholding indicated oral anticoagulation.
How does the HAS-BLED score integrate with EHR and health informatics workflows?
In EHR clinical decision support (CDS) systems, the HAS-BLED score is computed automatically alongside the CHA₂DS₂-VASc score at the point of anticoagulant prescribing by aggregating structured patient age, systolic blood pressure vitals, LOINC renal/hepatic lab panels, Rosendaal INR Time in Therapeutic Range (TTR), SNOMED CT/ICD-10 stroke and bleeding history codes, and RxNorm antiplatelet/NSAID medication records.
